Join
Live feed
·
PRReleasevia Quantisnow
Sarepta Therapeutics Inc. logo

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

ByQuantisnow·Wall Street's wire, on your screen.
SRPT· Sarepta Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SRPT (Sarepta Therapeutics Inc.) and more on Quantisnow.